(lp0
S"NEUROCRINE BIOSCIENCES, INC.  Files An 8-K Other Events Market Exclusive - Mar 13, 2017 On March 13, 2017, Neurocrine Biosciences, Inc.  announced it had completed the screening process and initiated hiring the Company's field-based sales representatives of approximately 140 professionals.Summary of Stock Move: Neurocrine Biosciences, Inc.  - Is storiesThe Piper Jaffray Companies Reiterates Outperform Rating for Neurocrine ... - Petro Global News 24"
p1
aS'Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros MD ... PR Newswire  - Jan 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre &quot;DA&quot; Gros M.D.Neurocrine Biosciences  Gains as FDA Cancels INGREZZA AdCom; PDUFA Date ... - StreetInsider.comWhat Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. ? - Insider Monkey '
p2
aS'Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth ... PR Newswire  - Feb 7, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc.  announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, February 14, 2017.Christopher Flint Obrien Sells 1500 Shares of Neurocrine Biosciences, Inc ... - Sports Perspectives'
p3
aS'Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin ... PR Newswire  - Dec 21, 2016 SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurological and endocrine related disorders, announced today that Timothy P. Coughlin will be stepping down from his&nbsp;...'
p4
aS'Neurocrine Biosciences Building Toward Bigger Things Seeking Alpha - Feb 16, 2017 Neurocrine is heading toward multiple major milestones in 2017, including potential approval of its first drug, an NDA filling for another, and an important gating Phase II study.'
p5
aS'Reviewing the Numbers for Neurocrine Biosciences, Inc.  Rives Journal - Mar 16, 2017 Neurocrine Biosciences, Inc.  currently has a Gross Margin  ratio of -0.057247. Robert Novy-Marx has provided investors with insights on finding high-quality value stocks.Investor Update on Shares of Neurocrine Biosciences, Inc.  - Davidson Register'
p6
aS"How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Lannett ... PR Newswire  - Mar 17, 2017 Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Drugs - Generic equities this morning: Neurocrine Biosciences Inc. , Lannett Company Inc. , Rigel Pharmaceuticals Inc. (NASDAQ:&nbsp;..."
p7
aS'The Positive Investment Case For Neurocrine Biosciences Seeking Alpha - Feb 3, 2017 Founded in 1996, Neurocrine Biosciences is a San Diego, CA,-based biopharmaceutical concern with two late-stage clinical programs that are focused on neurological and endocrine based diseases and disorders.How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke ... - PR Newswire Pay Close Attention To 2 Stock Analyst Ratings: PerkinElmer, Inc. (NYSE:PKI ... - The Voice Registrar'
p8
aS"NEUROCRINE BIOSCIENCES, INC.  Files An 8-K Results of Operations ... Market Exclusive - Feb 15, 2017 Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders.Neurocrine Biosciences'  CEO Kevin Gorman on Q4 2016 Results - Earnings ... - Seeking Alpha"
p9
aS'Has Neurocrine Biosciences Hit A Jackpot With Ingrezza? Seeking Alpha - Dec 5, 2016 Today, Neurocrine Biosciences  is at the cusp of a major transformation, from being an R&amp;D focused company to a commercial organization.'
p10
a.